Lin, Ziqing | Search NASA

DOE OSTI2026

Activationof Oxygen Evolution Electrocatalysis viaReduced Ruthenium–Oxygen–Ruthenium Coordination

Noble metal oxides such as RuO2 are the state-of-the-art electrocatalysts for anodic reactions in acidic electrolytes, but their scarcity and moderate activity greatly limit emerging renewable energy technologies. Here, we show that oxidized overlayers of ruthenium on earth-abundant manganese oxide (MnO2/o-RuOx) nanocrystal supports exhibit Ru chemical states associated with reduced Ru–O–Ru coordination that enable dynamic switching of hydrogen bonding, with *OH intermediates hydrogen bonding to surface O and *OOH intermediates bonding to protruding RuOx clusters. The resulting electrocatalysts exhibit an overpotential of 218.9 ± 0.3 mV at 10 mA cm–2 for the oxygen evolution reaction in acid, corresponding to a 2425% increase in Ru mass activity compared to RuO2, enabling the construction of electrolyzers that achieved 3 A cm–2 at 1.646 V, 5.54 A cm–2 at 1.8 V, and exhibited over 3000-h stability at 100 mA cm–2. These findings motivate further efforts to develop nanomaterials that harness reduced Ru–O–Ru coordination to enable emerging renewable energy technologies.

58 GEOSCIENCES↗

DOE OSTI2020

Interlaboratory Study for Characterizing Monoclonal Antibodies by Top-Down and Middle-Down Mass Spectrometry

The Consortium for Top-Down Proteomics (www.topdownproteomics.org) launched the present study to assess the state of top-down mass spectrometry (TD MS) and middle-down mass spectrometry (MD MS) for characterizing monoclonal antibody (mAb) primary structures, including their modifications. To meet the needs of the rapidly growing therapeutic antibody market, it is important to develop analytical strategies to characterize the heterogeneity of a therapeutic product’s primary structure reliably and reproducibly. The major objective of the present study was to determine whether current TD/MD MS technologies and protocols can add value to the more commonly employed bottom-up approaches, such as confirming protein integrity, sequencing variable domains, ruling out artefacts, and revealing modifications and their locations. A panel of three mAbs was selected and centrally provided to twenty laboratories worldwide for the analysis: Sigma mAb standard (SiLuLite), NIST mAb standard, and the therapeutic mAb Herceptin (trastuzumab). A variety of different MS instrument platforms and ion dissociation techniques were employed. Overall, the present study confirms that MD/TD MS strategies are valuable and readily available tools in laboratories worldwide. They provide complementary information to the bottom-up approach and can add unique information, which may be crucial for comprehensive mAb characterization. The current limitations, as well as possible solutions to overcome them, are also outlined. One of the limitations revealed by the results of the present study is that the expert knowledge in both experiment and data analysis is indispensable to practice TD/MD MS, but the number of TD/MD MS experts is still very low.

59 BASIC BIOLOGICAL SCIENCES↗